Induction chemotherapy and molecular MRD influence outcomes in KMT2A -rearranged AML Available to Purchase

2.

Grimwade

D

,

Hills

RK

,

Moorman

AV

, et al.

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

.

Blood

.

2010

;

116

(

3

):

354

-

365

.

3.

Meyer

C

,

Larghero

P

,

Almeida Lopes

B

, et al.

The KMT2A recombinome of acute leukemias in 2023

.

Leukemia

.

2023

;

37

(

5

):

988

-

1005

.

4.

Bill

M

,

Mrózek

K

,

Kohlschmidt

J

, et al.

Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/ KMT2A

.

Proc Natl Acad Sci USA

.

2020

;

117

(

42

):

26340

-

26346

.

5.

Krauter

J

,

Wagner

K

,

Schäfer

I

, et al.

Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data–based meta-analysis of the German Acute Myeloid Leukemia Intergroup

.

J Clin Oncol

.

2009

;

27

(

18

):

3000

-

3006

.

6.

Chen

Y

,

Kantarjian

H

,

Pierce

S

, et al.

Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation

.

Leukemia

.

2013

;

27

(

4

):

836

-

842

.

7.

Vetro

C

,

Haferlach

T

,

Meggendorfer

M

, et al.

Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-rearranged acute myeloid leukemia

.

Cancer Genet

.

2020

;

240

:

15

-

22

.

8.

Döhner

H

,

Wei

AH

,

Appelbaum

FR

, et al.

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

.

Blood

.

2022

;

140

(

12

):

1345

-

1377

.

9.

Hernández-Sánchez

A

,

González

T

,

Sobas

M

, et al.

Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study

.

Leukemia

.

2024

;

38

(

9

):

1929

-

1937

.

10.

Issa

GC

,

Zarka

J

,

Sasaki

K

, et al.

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements

.

Blood Cancer J

.

2021

;

11

(

9

):

162

.

11.

Schoch

C

,

Schnittger

S

,

Klaus

M

,

Kern

W

,

Hiddemann

W

,

Haferlach

T

.

AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases

.

Blood

.

2003

;

102

(

7

):

2395

-

2402

.

12.

Issa

GC

,

Aldoss

I

,

Thirman

MJ

, et al.

Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)

.

J Clin Oncol

.

2025

;

43

(

1

):

75

-

84

.

13.

Loo

S

,

Potter

N

,

Ivey

A

, et al.

Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia

.

Blood

.

2024

;

144

(

24

):

2554

-

2557

.

14.

Wang

L

,

Chen

Y

,

Zang

M

, et al.

Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a-rearranged acute myeloid leukemia

.

Cancer

.

2025

;

131

(

2

):

e35717

.

15.

Scholl

C

,

Schlenk

RF

,

Eiwen

K

, et al.

The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia

.

Haematologica

.

2005

;

90

(

12

):

1626

-

1634

.

16.

Mitterbauer

G

,

Zimmer

C

,

Pirc-Danoewinata

H

, et al.

Monitoring of minimal residual disease in patients with MLL–AF6-positive acute myeloid leukaemia by reverse transcriptase polymerase chain reaction

.

Br J Haematol

.

2000

;

109

(

3

):

622

-

628

.

17.

Mitterbauer

G

,

Zimmer

C

,

Fonatsch

C

, et al.

Monitoring of minimal residual leukemia in patients with MLL-AF9 positive acute myeloid leukemia by RT-PCR

.

Leukemia

.

1999

;

13

(

10

):

1519

-

1524

.

18.

Matsuo

H

,

Iijima-Yamashita

Y

,

Yamada

M

, et al.

Monitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia

.

Pediatr Int

.

2018

;

60

(

1

):

41

-

46

.

19.

Juul-Dam

KL

,

Ommen

HB

,

Nyvold

CG

, et al.

Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia

.

Br J Haematol

.

2020

;

190

(

2

):

198

-

208

.

20.

Huang

S

,

Yang

H

,

Li

Y

, et al.

Prognostic significance of mixed-lineage leukemia (MLL) gene detected by real-time fluorescence quantitative PCR assay in acute myeloid leukemia

.

Med Sci Monit

.

2016

;

22

:

3009

-

3017

.

21.

Burnett

AK

,

Hills

RK

,

Nielsen

OJ

, et al.

A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 trial

.

Leukemia

.

2018

;

32

(

12

):

2693

-

2697

.

22.

Burnett

A

,

Cavenagh

J

,

Russell

N

, et al.

Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m² with 6 mg/m² in the NCRI AML17 trial

.

Haematologica

.

2016

;

101

(

6

):

724

-

731

.

23.

Burnett

AK

,

Russell

NH

,

Hills

RK

, et al.

A randomized comparison of daunorubicin 90 mg/m² vs 60 mg/m² in AML induction: results from the UK NCRI AML17 trial in 1206 patients

.

Blood

.

2015

;

125

(

25

):

3878

-

3885

.

24.

Burnett

AK

,

Russell

NH

,

Hills

RK

, et al.

Defining the optimal total number of chemotherapy courses in younger patients with acute myeloid leukemia: a comparison of three versus four courses

.

J Clin Oncol

.

2021

;

39

(

8

):

890

-

901

.

25.

Russell

NH

,

Wilhelm-Benartzi

C

,

Othman

J

, et al.

Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed AML and overall survival in patients with NPM1 and FLT3 mutations

.

J Clin Oncol

.

2024

;

42

(

10

):

1158

-

1168

.

26.

Othman

J

,

Wilhelm-Benartzi

C

,

Dillon

R

, et al.

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial

.

Blood Adv

.

2023

;

7

(

16

):

4539

-

4549

.

27.

Potter

N

,

Xavier

S

,

Auken

P

, et al.

Targeted RNA sequencing frequently identifies high-risk fusion genes in younger adults with otherwise intermediate-risk AML and isolated FLT3-ITD [abstract]

.

HemaSphere

.

2024

;

8

(

S1

). Abstract P449.

28.

Freeman

SD

,

Hills

RK

,

Virgo

P

, et al.

Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations

.

J Clin Oncol

.

2018

;

36

(

15

):

1486

-

1497

.

29.

DiNardo

CD

,

Jen

W-Y

,

Takahashi

K

, et al.

Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia

.

Leukemia

.

2025

;

39

(

4

):

854

-

863

.